Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 20, 2012

Primary Completion Date

August 6, 2021

Study Completion Date

August 6, 2021

Conditions
Arterial CalcificationCD73 Deficiency
Interventions
DRUG

Etidronate

Didronel (etidronate disodium)- Didronel tablets contain either 200 mg or 400 mg of etidronate disodium, the disodium salt of (1-hydroxyethylidene) diphosphonic acid, for oral administration. This compound, also known as EHDP. regulates bone metabolism. It is a white powder, highly soluble in water. The 400 mg tablets are white capsule-shaped tablets with ED 400 on one side and G on the other side.

DEVICE

MRI Scan

Visit on day 0 and visit at 36 month - Exploratory MRI studies may be employed to evaluate the lumen of the artery and degree of collateral vessels, given that the high degree of calcification is precluding that evaluation by CT.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT01585402 - Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC) | Biotech Hunter | Biotech Hunter